Sun Pharmaceutical Declines 2.40%: Mixed Option Activity Highlights Market Caution

25 May: Flat Quarterly Performance Amid Margin Pressure

Sun Pharmaceutical Industries Ltd reported a flat quarterly financial performance for the quarter ended March 2026, with profit before tax (PBT) at ₹3,092.84 crores, down 13.9% compared to the preceding four-quarter average. Profit after tax (PAT) also declined by 10.6% to ₹2,714.03 crores. This marked a significant pause in the company’s previously positive earnings momentum, reflecting emerging challenges in margin expansion and operational efficiency.

The stock closed at Rs.1,845.20 on 25 May, down 2.43% from the previous close, despite remaining near its 52-week high of Rs.1,917.15. The contraction in profitability margins suggests rising costs or pricing pressures, consistent with sector-wide challenges in Pharmaceuticals & Biotechnology, including regulatory scrutiny and competitive pressures in key markets.

25 May: Surge in Call Option Activity Signals Bullish Positioning

On the same day, Sun Pharma emerged as the most actively traded stock in call options, particularly at the ₹1860 strike price. A total of 13,543 call contracts were traded, generating a turnover of approximately ₹16.92 crores, with open interest at 5,261 contracts. The underlying stock price was Rs.1,845.20, just 3.73% below the 52-week high, indicating investor optimism for a potential upside breakout.

Despite a modest 0.04% gain on the day, the robust call option volumes reflect a medium- to long-term uptrend supported by the stock trading above its key moving averages. This bullish positioning contrasts with the slight price dip, suggesting traders were anticipating a rebound or sustained rally post-expiry.

25 May: Heavy Put Option Activity Reflects Bearish Hedging

Contrasting the bullish call activity, Sun Pharma also saw significant put option volumes on 25 May, signalling increased bearish positioning and hedging. The 1820 strike put option led with 9,921 contracts traded, turnover of ₹102.78 lakhs, and open interest of 2,436 contracts. The 1800 strike followed with 7,274 contracts and an open interest of 3,315 contracts, while the 1840 strike had 7,061 contracts traded.

This clustering of put options near the current stock price suggests investors were actively protecting long positions or speculating on a near-term correction. The stock’s slight underperformance relative to its sector and trading below its 5-day moving average reinforced this cautious sentiment.

26 May: Continued Put Option Activity Amid Three-Day Decline

On 26 May, Sun Pharma remained the most active stock in put option trading, with the 1820 strike put options seeing 1,629 contracts traded and open interest of 2,000 contracts. The stock closed at Rs.1,833.40, down 0.43% on the day, marking a three-day consecutive decline totalling 3.33%.

Despite the broader Sensex gaining 0.13%, Sun Pharma’s underperformance and the heavy put buying indicate growing investor caution. The stock remained above its longer-term moving averages but below the 5-day average, signalling short-term weakness. This technical divergence likely contributed to the increased demand for downside protection ahead of expiry.

29 May: Week Closes with a 2.40% Decline Amid Mixed Sentiment

Sun Pharma’s stock closed the week at Rs.1,800.90, down 2.40% from the previous Friday’s close of Rs.1,845.20. This decline contrasts with the Sensex’s flat performance, highlighting the stock’s relative weakness amid mixed market signals. The week’s price action was influenced by the flat quarterly results, margin pressures, and the contrasting bullish and bearish option market activity.

The stock’s volume increased towards the week’s end, with 146,179 shares traded on 29 May, reflecting heightened investor activity amid the price correction. The interplay of strong call option interest and heavy put option hedging underscores a market grappling with uncertainty over near-term direction.

Key Takeaways

Positive Signals: Despite the weekly decline, Sun Pharma maintains a strong long-term uptrend supported by its position above key moving averages and a robust market capitalisation of over ₹4.4 lakh crores. The surge in call option activity at the ₹1860 strike price ahead of expiry indicates underlying bullish sentiment and expectations of a potential rebound.

Cautionary Signals: The flat quarterly performance with declining PBT and PAT highlights margin pressures and operational challenges. Heavy put option volumes clustered near current prices reflect investor hedging and bearish positioning, signalling caution amid short-term volatility. The recent downgrade from Strong Buy to Buy in the Mojo Score further underscores a tempered outlook.

Overall, the week’s mixed signals from fundamental results and options market activity suggest that Sun Pharma is navigating a period of consolidation and uncertainty. Investors should monitor upcoming earnings and sector developments closely for clearer directional cues.

Conclusion

Sun Pharmaceutical Industries Ltd’s week ending 29 May 2026 was characterised by a delicate balance between optimism and caution. The flat quarterly results amid margin pressures tempered enthusiasm, while the options market revealed divergent views with both bullish call and bearish put activity. The stock’s 2.40% weekly decline contrasted with the Sensex’s stability, reflecting company-specific challenges within a complex sector environment.

As the expiry passed, the stock’s near-term direction remains uncertain, with technical indicators showing short-term weakness despite a solid long-term foundation. Investors and traders alike should remain vigilant, considering both the risks highlighted by put option hedging and the potential for recovery signalled by call option interest. The evolving sector dynamics and regulatory landscape will continue to play a pivotal role in shaping Sun Pharma’s trajectory in the weeks ahead.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →